About Annelien Morlion
Reliable cancer biomarkers are essential for early diagnosis, monitoring treatment response, and guiding follow-up care. While tissue biopsies are still the gold standard in cancer management, less invasive approaches - such as analyzing body fluids through liquid biopsies - may offer significant advantages. These include the potential for earlier detection, fewer surgical procedures, and the ability to monitor disease over time through repeated sampling.
Among the promising biomarker candidates are RNAs: dynamic molecules produced in response to a cell’s needs. My research focuses on RNAs released in body fluids. By applying computational methods to RNA sequencing data from liquid biopsy samples, I aim to uncover cancer-related signals within cell-free RNA profiles that can support more effective detection and cancer management.
